Lead sponsor
Denali Therapeutics Inc.
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
2
Ongoing
169
Total enrollment
35
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 1/2
1
Trials by status
Recruiting
1
Active, not recruiting
1
Completed
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)GRN mutation requiredPh 1/2Active, not recruiting85